Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Jorssen

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Biochemical Pharmacology|April 12, 2020
Eosinophil diversity in asthmaGlenn Van Hulst, Hashini M Batugedara, Joseph Jorssen, et al.
The European Respiratory Journal|September 3, 2021
Anti-IL5 mepolizumab minimally influences residual blood eosinophils in severe asthmaGlenn Van Hulst, Joseph Jorssen, Nathalie Jacobs, et al.
The European Respiratory Journal|July 1, 2022
Reply: <i>Ex vivo</i> SOCS3 gene responsiveness to alarmins in eosinophils of mepolizumab-treated patients is as yet of unknown biological significanceGlenn Van Hulst, Joseph Jorssen, Nathalie Jacobs, et al.
Immunity|May 22, 2024
Single-cell proteomics and transcriptomics capture eosinophil development and identify the role of IL-5 in their lineage transit amplificationJoseph Jorssen, Glenn Van Hulst, Kiréna Mollers, et al.
The Journal of Experimental Medicine|January 28, 2021
Loss of tRNA-modifying enzyme Elp3 activates a p53-dependent antitumor checkpoint in hematopoiesisAdeline Rosu, Najla El Hachem, Francesca Rapino, et al.
Science Immunology|January 30, 2026
Cross-species cellular mapping and humanization of Fcγ receptors to advance antibody modelingKarel F A Van Damme, Dorine Sichien, Katrien Van der Borght, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Biochemical Pharmacology|April 12, 2020
Eosinophil diversity in asthmaGlenn Van Hulst, Hashini M Batugedara, Joseph Jorssen, et al.
The European Respiratory Journal|September 3, 2021
Anti-IL5 mepolizumab minimally influences residual blood eosinophils in severe asthmaGlenn Van Hulst, Joseph Jorssen, Nathalie Jacobs, et al.
The European Respiratory Journal|July 1, 2022
Reply: <i>Ex vivo</i> SOCS3 gene responsiveness to alarmins in eosinophils of mepolizumab-treated patients is as yet of unknown biological significanceGlenn Van Hulst, Joseph Jorssen, Nathalie Jacobs, et al.
Immunity|May 22, 2024
Single-cell proteomics and transcriptomics capture eosinophil development and identify the role of IL-5 in their lineage transit amplificationJoseph Jorssen, Glenn Van Hulst, Kiréna Mollers, et al.
The Journal of Experimental Medicine|January 28, 2021
Loss of tRNA-modifying enzyme Elp3 activates a p53-dependent antitumor checkpoint in hematopoiesisAdeline Rosu, Najla El Hachem, Francesca Rapino, et al.
Science Immunology|January 30, 2026
Cross-species cellular mapping and humanization of Fcγ receptors to advance antibody modelingKarel F A Van Damme, Dorine Sichien, Katrien Van der Borght, et al.
Pageof 1